Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "products"

2384 News Found

Enzymit and Cosun chart breakthrough in cell-free hyaluronic acid production
Biopharma | November 14, 2025

Enzymit and Cosun chart breakthrough in cell-free hyaluronic acid production

Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering


BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”
News | November 12, 2025

BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”

The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance


Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics
R&D | November 12, 2025

Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics

The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line


Glenmark secures China approval for Ryaltris
Drug Approval | November 10, 2025

Glenmark secures China approval for Ryaltris

The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline


FUJIFILM Sonosite unveils new portable ultrasound system ‘ Sonosite MT’
Medical Device | November 07, 2025

FUJIFILM Sonosite unveils new portable ultrasound system ‘ Sonosite MT’

The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups


UPS acquires Andlauer for $1.6 billion to strengthen global healthcare network
Supply Chain | November 07, 2025

UPS acquires Andlauer for $1.6 billion to strengthen global healthcare network

The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings


Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Drug Approval | November 06, 2025

Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia

Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval